Endocrine hypertension

Checking blood pressure

Endocrine hypertension

Endocrine hypertension refers to high blood pressure (hypertension) caused by the abnormal production of hormones. 

The most common form of endocrine hypertension is primary aldosteronism (PA), also known as Conn syndrome.  In PA, the adrenal glands, which sit on top of each kidney, produce too much aldosterone (a hormone that retains salt in the body). This can lead to excess salt and fluid retention and, subsequently an increase in blood pressure. It also increases the risk of heart arrhythmia, heart attack and stroke more than ordinary forms of hypertension.

Primary aldosteronism affects 5 to 10 per cent of those with hypertension but often goes undiagnosed. It is treatable with medication and/or surgery, depending on the cause.

VIEW VIDEO | Associate Professor Jun Yang discusses primary aldosteronism

Our primary aldosteronism research

For more than a decade, clinicians and researchers at Hudson Institute have strived to improve the care of patients with primary aldosteronism. The development of diagnostic and management guidelines for primary aldosteronism at Monash Health led to a 40-fold increase in the number of patients diagnosed over a 10-year period (2010-2020).

This progress paved the way for the establishment of Victoria’s first dedicated Endocrine Hypertension Service in 2017, integrating medical research into routine clinical practice to enhance the standard of care for affected individuals.

Establishment of Primary Aldosteronism Centre of Excellence (PACE)

In 2024, the Primary Aldosteronism Centre of Excellence (PACE), led by Hudson Institute was established, bringing together a national collaboration of researchers, healthcare professionals, researchers, policy makers and consumers. This Centre of Research Excellence program was funded by the Federal Government with the goal to revolutionise the diagnosis and management of PA, to improve health outcomes and reduce the burden of hypertension and chronic disease.

PACE aims to:  

  • Optimise the timely and accurate diagnosis of PA through collaborative research and transformation of clinical practice guidelines and diagnostic methods
  • Identify genetic and environmental factors and novel biomarkers, to underpin personalised diagnostic tests and treatments
  • Create the research environment and clinical trial capabilities to build capacity for world-leading research in PA.

READ MORE including information for researchers, patients and doctors at Primary Aldosteronism Centre of Excellence

PA FAQs

Signs and symptoms of primary aldosteronism

Causes of primary aldosteronism

Diagnosis of primary aldosteronism

Treatment of primary aldosteronism

Long term effects of primary aldosteronism

High blood pressure and primary aldosteronism explained

Caused by a hormone imbalance, primary aldosteronism is often undiagnosed or given incorrect treatment. Hudson Institute research teams are working to improve the diagnosis and treatment of this serious but potentially curable disease and related conditions.

Associate Professor Jun Yang explains more about her research on high blood pressure and primary aldosteronism with Dr Norman Swan on the ABC Health Report.

Share this page